Understand the source comparison
Female Sexual Health Peptides 2026 Update: Comparison of Research-Stage Compounds
The following table summarizes the peptide compounds under active investigation for female sexual health applications as of the 2026 research update: PT-141 (Bremelanotide) MC4R agonist. Dopamine modulation HSDD (hypoactive sexual desire disorder) FDA-approved
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes the peptide compounds under active investigation for female sexual health applications as of the 2026 research update:
- PT-141 (Bremelanotide)
- MC4R agonist. Dopamine modulation
- HSDD (hypoactive sexual desire disorder)
- FDA-approved (Vyleesi)
- Subcutaneous injection
- High. Phase 3 RCTs
- Kisspeptin-54
- KISS1R agonist. GnRH pathway activation
- Arousal disorders, HSDD
- Phase 2
- Intravenous (investigational intranasal)
- Moderate. Pilot studies
- Oxytocin analogs
- OXTR agonist. Bonding and arousal circuits
- Anorgasmia, arousal disorders
- Preclinical to Phase 1
- Intranasal, subcutaneous
- Low. Mixed results
- VIP (Vasoactive Intestinal Peptide)
- NO pathway. Vascular smooth muscle relaxation
- Arousal disorder, vaginal atrophy
- Intravaginal gel, systemic analogs
- Moderate. Small trials
- Adrenomedullin (AM)
- CALCRL agonist. Vasodilation
- Arousal disorder
- Preclinical
- Investigational
- Low. Animal models only
- Melanocortin analogs (non-PT-141)
- MC3R/MC4R modulation
- HSDD, arousal disorders
- Phase 1–2
- Subcutaneous, intranasal
- Low to moderate